MedTrace Logo

Trachoma Elimination Follow-up

NCT00221364 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2015-07-15

No results posted yet for this study

Summary

The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.

Conditions

  • Trachoma
  • Chlamydia

Interventions

DRUG

Mass treatment with oral azithromycin to an entire village

Sponsors & Collaborators

Principal Investigators

  • Thomas M Lietman, MD · Proctor Foundation, UCSF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • Ethiopia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00221364 on ClinicalTrials.gov